| Autor: |
de Quadros Onófrio F; Department of Gastroenterology and Hepatology, Santa Casa Hospital/Federal University of Health Sciences of Porto Alegre (UFCSPA), Rua São Francisco, 469/1203, Porto Alegre, 90620-070, Brazil. fqonofrio@gmail.com., Lima JCP; Department of Gastroenterology and Hepatology, Santa Casa Hospital/Federal University of Health Sciences of Porto Alegre (UFCSPA), Rua São Francisco, 469/1203, Porto Alegre, 90620-070, Brazil., Watte G; The Post-Graduation Program in Chest Medicine Sciences, Santa Casa Hospital, Porto Alegre, Brazil., Lehmen RL; Department of Anesthesiology, Santa Casa Hospital, Porto Alegre, Brazil., Oba D; Department of Gastroenterology and Hepatology, Santa Casa Hospital/Federal University of Health Sciences of Porto Alegre (UFCSPA), Rua São Francisco, 469/1203, Porto Alegre, 90620-070, Brazil., Camargo G; Department of Gastroenterology and Hepatology, Santa Casa Hospital/Federal University of Health Sciences of Porto Alegre (UFCSPA), Rua São Francisco, 469/1203, Porto Alegre, 90620-070, Brazil., Dos Santos CEO; Department of Gastroenterology and Endoscopy, Santa Casa de Caridade de Bagé, Bagé, Brazil. |
| Abstrakt: |
Background Acute pancreatitis is the most common complication after ERCP, occurring in about 4 % of the procedures. Only the placement of pancreatic duct prosthesis and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) have shown benefit in the prevention of post-ERCP pancreatitis (PEP). Although the benefit of rectal administration of indomethacin or diclofenac is recommended by some studies and society guidelines especially in a selected group of high-risk patients, there is so far, no standardization of time or route of NSAID administration. The aim of the current study is to investigate the role of an intravenous NSAID administered before the procedure for PEP prevention. Methods In this randomized double-blind clinical trial, all consecutive patients who underwent ERCP were randomized to receive saline infusion with ketoprofen or saline, immediately before the procedure. Results A total of 477 patients were enrolled and completed follow-up. The majority of patients (72.1 %) had bile duct stones, and only 1.5 % had a clinical suspicion of sphincter of Oddi dysfunction. PEP developed in 5 of 253 (2 %) patients in the placebo group and in 5 of 224 (2.2 %) patients in the ketoprofen group (p = 1.). Conclusions Intravenous administration of ketoprofen immediately prior to ERCP did not result in reduction in PEP in a general population of ERCP patients. |
Full text from SpringerLink